Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Multicohort Study of JNJ-68284528 (BCMA-directed CAR-T) in Multiple Myeloma
2018-004124-10Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: MRD negative rate. Started Nov 2019; status: active.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-004124-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004124-10.